[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:chronic-myelomonocytic-leukemia:idh1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Chronic Myelomonocytic Leukemia","IDH1 Gene",5,[8,16,22,28,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06566742","A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic\u002FSyndromes\u002FChronic Myelomonocytic Leukemia.",[12],"Phase 2","RECRUITING","2026-08-26T02:18:38.077159Z","2026-07-19T19:36:05.036073Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06668584","A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies",[12],"2026-08-26T02:19:02.550788Z","2026-05-05T02:47:14.264276Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",[12],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.732946Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06543381","Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant",[32],"Phase 1","2026-08-26T02:15:01.639696Z","2026-04-29T02:57:57.159415Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":26,"content_modified":39},"NCT06291987","Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation",[32],"2026-05-05T02:43:27.513961Z"]